<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05015660</url>
  </required_header>
  <id_info>
    <org_study_id>2021-7452</org_study_id>
    <nct_id>NCT05015660</nct_id>
  </id_info>
  <brief_title>Conduction System Pacing With Left Bundle Branch Pacing as Compared to Standard Right Ventricular Pacing</brief_title>
  <official_title>LEFT Bundle Pacing vs Standard Right Ventricular Pacing for Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High burden right ventricular (RV) pacing has been shown to increase cardiovascular&#xD;
      mortality, incidence of heart failure (HF), worsen left ventricular (LV) function and&#xD;
      accelerate the development of atrial fibrillation (AF). High percentage ventricular pacing&#xD;
      and wider paced QRS in the setting of normal baseline LV ejection fractions have consistently&#xD;
      been shown to be independent risk factors for pacing-induced cardiomyopathy. Left bundle&#xD;
      branch pacing (LBBP) has recently emerged as a potential alternative pacing mechanism that&#xD;
      may avoid LV dyssynchrony and pacing-induced LV dysfunction by mimicking native electrical&#xD;
      conduction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this vanguard study, the investigators hypothesize that in patients with high degree AV&#xD;
      block and normal to mild LV dysfunction (LVEF &gt;= 50%), patients undergoing LBBP will&#xD;
      demonstrate a significantly lower indexed LV end-systolic volume (LVESVi) as compared to&#xD;
      those undergoing RV pacing over 24 months follow-up. The investigators will demonstrate that&#xD;
      recruitment is feasible, LBBP can be successfully performed with reproducible and consistent&#xD;
      results, and that LVESVi will prove to be a suitable efficacy endpoint to inform the design&#xD;
      and proceed with the pivotal LEFT-HF study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective open-label randomized controlled trial (1:1) with blinded outcome adjudication</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinded outcome adjudication</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular end systolic volume index</measure>
    <time_frame>24 months</time_frame>
    <description>Echo parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful implant</measure>
    <time_frame>30 days</time_frame>
    <description>Implant success after 4 attempts at left bundle pacing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of recruitment</measure>
    <time_frame>18 months</time_frame>
    <description>100 patients over 7 centers over 18 months recruitment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>24 months</time_frame>
    <description>CV-related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New visit for Heart Failure</measure>
    <time_frame>24 months</time_frame>
    <description>Heart failure visit is defined as: i) Emergency department visit or hospitalization for signs and symptoms of HF that is responsive to oral or intravenous diuretics ii) intensification of therapy defined as outpatient intravenous diuretic therapy, and iii) device upgrade to cardiac resynchronization therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>24 months</time_frame>
    <description>Total mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular ejection fraction</measure>
    <time_frame>24 months</time_frame>
    <description>Echo parameter, change from baseline to 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NTproBNP level</measure>
    <time_frame>24 months</time_frame>
    <description>From baseline to 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation progression</measure>
    <time_frame>24 months</time_frame>
    <description>Atrial fibrillation burden as noted on pacemaker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of new tricuspid regurgitation</measure>
    <time_frame>24 months</time_frame>
    <description>More than mild TR from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Mitral regurgitation</measure>
    <time_frame>24 months</time_frame>
    <description>Progression/Development from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lead parameter</measure>
    <time_frame>24 months</time_frame>
    <description>stability of impedance, sensing, thresholds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Improvement</measure>
    <time_frame>Evaluated at 1, 12, and 24 months, measure as compared to baseline</time_frame>
    <description>Health related quality of life score: Short Form 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of procedure and long-term safety</measure>
    <time_frame>24 months</time_frame>
    <description>Procedural and long-term safety of left bundle pacing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pacemaker DDD</condition>
  <condition>Heart Block</condition>
  <arm_group>
    <arm_group_label>left bundle branch pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Right ventricular pacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Left bundle branch pacing lead (Select Secure 3830 lead)</intervention_name>
    <description>Implantation of a left bundle branch pacing lead via sheath, to perform selective or non-selective pacing</description>
    <arm_group_label>left bundle branch pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Right ventricular active fixation lead</intervention_name>
    <description>Active fixation lead (standard)</description>
    <arm_group_label>Right ventricular pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Patients with an ejection fraction of ≥50%&#xD;
&#xD;
          3. Patients with an indication for ventricular pacing and high-degree atrioventricular&#xD;
             block where the degree of anticipated RV pacing is &gt;90% including:&#xD;
&#xD;
               1. Third degree AV block&#xD;
&#xD;
               2. Symptomatic or asymptomatic second-degree AV block&#xD;
&#xD;
               3. First degree AV block ≥ 280ms with a narrow QRS, or ≥ 240ms with an&#xD;
                  intraventricular delay (QRS duration ≥120ms)&#xD;
&#xD;
          4. Echocardiogram within the last 3 months, with ability to have DICOM images&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Indication for an implantable cardioverter defibrillator&#xD;
&#xD;
          2. Presence of a mechanical tricuspid valve&#xD;
&#xD;
          3. Any prior attempt at implantation of an ICD, CRT, HBP, or LBBP&#xD;
&#xD;
          4. Lack of capacity to consent&#xD;
&#xD;
          5. Other serious medical condition with life expectancy of &lt;2 years&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
          7. Patients in whom the conduction system abnormality is expected to be transient or&#xD;
             recover over time&#xD;
&#xD;
          8. Patients with permanent atrial fibrillation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacqueline Joza, MD MSc</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>43158</phone_ext>
    <email>jacqueline.joza@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fiorella Rafti, PhD</last_name>
    <phone>514-934-1934</phone>
    <email>fiorella.rafti@mail.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McGill University Health Centre-Research Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Y2T6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Jacqueline Joza</investigator_full_name>
    <investigator_title>Cardiac electrophysiologist</investigator_title>
  </responsible_party>
  <keyword>left bundle branch pacing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Block</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

